BACKGROUND: MicroRNAs (miRs) participate in many cardiac pathophysiological processes, including ischemia/reperfusion (I/R)-induced cardiac injury. Recently, we and others observed that miR-494 was downregulated in murine I/R-injured and human infarcted hearts. However, the functional consequence of miR-494 in response to I/R remains unknown. METHODS AND RESULTS: We generated a mouse model with cardiac-specific overexpression of miR-494. Transgenic hearts and wild-type hearts from multiple lines were subjected to global no-flow I/R with the Langendorff system. Transgenic hearts exhibited improved recovery of contractile performance over the reperfusion period. This improvement was accompanied by remarkable decreases in both lactate dehydrogenase release and the extent of apoptosis in transgenic hearts compared with wild-type hearts. In addition, myocardial infarction size was significantly reduced in transgenic hearts on I/R in vivo compared with wild-type hearts. Similarly, short-term overexpression of miR-494 in cultured adult cardiomyocytes demonstrated an inhibition of caspase-3 activity and reduced cell death on simulated I/R. In vivo treatment with antisense oligonucleotide miR-494 increased I/R-triggered cardiac injury relative to the administration of mutant antisense oligonucleotide miR-494 and saline controls. We further identified that 3 proapoptotic proteins (PTEN, ROCK1, and CaMKIIδ) and 2 antiapoptotic proteins (FGFR2 and LIF) were authentic targets for miR-494. Importantly, the Akt-mitochondrial signaling pathway was activated in miR-494-overexpressing myocytes. CONCLUSIONS: Our findings suggest that although miR-494 targets both proapoptotic and antiapoptotic proteins, the ultimate consequence is activation of the Akt pathway, leading to cardioprotective effects against I/R-induced injury. Thus, miR-494 may constitute a new therapeutic agent for the treatment of ischemic heart disease.
BACKGROUND: MicroRNAs (miRs) participate in many cardiac pathophysiological processes, including ischemia/reperfusion (I/R)-induced cardiac injury. Recently, we and others observed that miR-494 was downregulated in murine I/R-injured and humaninfarcted hearts. However, the functional consequence of miR-494 in response to I/R remains unknown. METHODS AND RESULTS: We generated a mouse model with cardiac-specific overexpression of miR-494. Transgenic hearts and wild-type hearts from multiple lines were subjected to global no-flow I/R with the Langendorff system. Transgenic hearts exhibited improved recovery of contractile performance over the reperfusion period. This improvement was accompanied by remarkable decreases in both lactate dehydrogenase release and the extent of apoptosis in transgenic hearts compared with wild-type hearts. In addition, myocardial infarction size was significantly reduced in transgenic hearts on I/R in vivo compared with wild-type hearts. Similarly, short-term overexpression of miR-494 in cultured adult cardiomyocytes demonstrated an inhibition of caspase-3 activity and reduced cell death on simulated I/R. In vivo treatment with antisense oligonucleotidemiR-494 increased I/R-triggered cardiac injury relative to the administration of mutant antisense oligonucleotidemiR-494 and saline controls. We further identified that 3 proapoptotic proteins (PTEN, ROCK1, and CaMKIIδ) and 2 antiapoptotic proteins (FGFR2 and LIF) were authentic targets for miR-494. Importantly, the Akt-mitochondrial signaling pathway was activated in miR-494-overexpressing myocytes. CONCLUSIONS: Our findings suggest that although miR-494 targets both proapoptotic and antiapoptotic proteins, the ultimate consequence is activation of the Akt pathway, leading to cardioprotective effects against I/R-induced injury. Thus, miR-494 may constitute a new therapeutic agent for the treatment of ischemic heart disease.
Authors: Aldo M Roccaro; Antonio Sacco; Changzhong Chen; Judith Runnels; Xavier Leleu; Feda Azab; Abdel Kareem Azab; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Nicholas Burwick; Lyuba Varticovski; Carl D Novina; Barrett J Rollins; Kenneth C Anderson; Irene M Ghobrial Journal: Blood Date: 2008-12-12 Impact factor: 22.113
Authors: Daehyun Baek; Judit Villén; Chanseok Shin; Fernando D Camargo; Steven P Gygi; David P Bartel Journal: Nature Date: 2008-07-30 Impact factor: 49.962
Authors: Steven S Chang; Wei Wen Jiang; Ian Smith; Luana M Poeta; Shahnaz Begum; Chad Glazer; Shannon Shan; William Westra; David Sidransky; Joseph A Califano Journal: Int J Cancer Date: 2008-12-15 Impact factor: 7.396
Authors: Arin B Aurora; Ahmed I Mahmoud; Xiang Luo; Brett A Johnson; Eva van Rooij; Satoshi Matsuzaki; Kenneth M Humphries; Joseph A Hill; Rhonda Bassel-Duby; Hesham A Sadek; Eric N Olson Journal: J Clin Invest Date: 2012-03-19 Impact factor: 14.808
Authors: Signe Altmäe; Jose A Martinez-Conejero; Francisco J Esteban; Maria Ruiz-Alonso; Anneli Stavreus-Evers; Jose A Horcajadas; Andres Salumets Journal: Reprod Sci Date: 2012-08-17 Impact factor: 3.060